ESH CLL2023-11-06T11:48:38+01:00


All video interviews from ESH 2nd Translational Research Conference on CLL

Lukas P. Frenzel summarizes the latest insights into resistance mechanisms to commonly used drugs such as BTK inhibitors and venetoclax. He explains how this knowledge affects daily clinical practice and/or proper patient selection, how patients can be handled who are resistant to both BTK and BCL2 inhibitors and highlights the role of MARCKS in fine-tuning responses to the BTK inhibitors.

Federico Pea draws attention to the most relevant differences between first-generation and next-generation BTK inhibitors observed at the pharmacokinetic level in terms of antitumor activity, how differences in kinase selectivity affect the tolerability of these drugs, which patient groups appear suitable for first-generation or next-generation BTK inhibitor therapy and outlines, from a pharmacologists point of view, what clinicians should keep in mind when treating CLL patients with BTK inhibitors.

Pierre Feugier explains which patients with CLL should preferably be treated with targeted agents rather than with chemotherapy or chemoimmunotherapy, the advantages of second-generation BTK inhibitors as compared to first-generation BTK inhibitors and discusses third-generation BTK inhibitors as well as his personal highlights reported at ESH CLL 2022.

Michael Hallek – COMING SOON

ESH 2nd Translational Research Conference on CLL

Lecture Board: Othman Al-Sawaf, MD; Wojciech Jurczak, MD, PhD
Medical Writer: Judith Moser, MD
Publishing Editor: Anna Fenzl, PhD

Additionally, we provide an independent report on the ESH CLL 2022 – Satellite Symposium “Inhibition of Bruton’s Tyrosine Kinase (BTK)

A key approach to managing and treating CLL patients” that was written without any interference from the pharmaceutical industry

Go to Top